Navigation Links
Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
Date:10/23/2007

rowing generic company as a partner to market our ophthalmic products in the USA. This partnership will help us to speedily introduce these products to the US market and explore other growth opportunities in the largest generic market of the world," said Mr. Suresh G. Kare, chairman & managing director of Indoco Remedies Limited.

Indoco and Amneal have already begun to identify several more ophthalmic products to pursue as well as other therapeutic categories and dosage forms. The two companies fully expect this agreement to expand significantly in the near term and to last many years.

With balanced input from both Amneal and Indoco, funding for developing these products will be equally shared. Likewise, the financial benefit from the sale of these products will be shared for years.

INDOCO REMEDIES Limited, headquartered in India, is a fully integrated research based pharmaceutical company, producing a wide range of high quality, affordable generic medicines trusted across the Globe. Indoco enjoys a dominant position in the domestic Indian market and its products are distributed in over 30 countries, including USA, Germany, UK and Australia. The state-of-the-art R&D facilities cover 70,000 sq ft, employ 100 scientists and support a manufacturing plant with approvals from USFDA, UK-MHRA, German Regulatory Authorities and ANVISA Brazil, reflecting the Company's commitment to being a leader in the generic space worldwide.

AMNEAL PHARMACEUTICALS LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufacturers and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are keys of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer b
'/>"/>

SOURCE Amneal Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 (HealthDay --, Treatment for lymphoma may lower ... and non-Hodgkin lymphoma, which are cancers of the body,s ... still in their reproductive years. For men, treatment for ... most men regain their fertility within two years of ... about the possibility of this significant side effect before ...
(Date:7/25/2014)... The American Society of Anesthesiologists (ASA) today announced ... (PSH) Learning Collaborative, a national initiative designed to ... surgery. More than 40 leading health care ... the collaborative, which will convene for the first ... July 25-26, in Schaumburg, Ill. , The PSH ...
(Date:7/25/2014)... The new report “Carbohydrase Market ... and Others), by Type (Amylases, Cellulases, and Others), ... Global Trends & Forecasts to 2019", by MarketsandMarkets, ... global Carbohydrase market with analysis of trends, opportunities, ... and values are forecasted on the basis of ...
(Date:7/25/2014)... Richardson, Texas (PRWEB) July 25, 2014 ... years of operations at their office location by expanding ... first of a kind comprehensive visual electro-physiology clinic. , ... and with years of experience in vision problems, patients ... studies can now take advantage of the implementation of ...
(Date:7/25/2014)... European liquid chromatography reagents report defines and segments the ... revenue. The liquid chromatography reagents market in Europe was ... estimated to grow to around $1581.8 million by 2018, ... 2018. , Browse through the TOC of the European ... the in-depth analysis provided. This also provides a glimpse ...
Breaking Medicine News(10 mins):Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4
... According to a study of patients, doctors and family ... When someone has a terminal illness, they may have ... 'living will'. For example they may not wish to ... realistic chance of recovery. But other people, even though ...
... better than conventional treatment for managing asthma attacks. ... immune cells known eosinophils increase// in the airways. ... how targeting this build up of eosinophils in ... asthma attack. ,The conventional treatment consists ...
... is observed that statins reduce the risk of heart attack ... and so lowers the risk of heart disease. This has ... the benefits for the elderly have not been so clear. ... the benefit of treatment with the statin drug pravastatin in ...
... new study observed that people reporting symptoms of anxiety were ... It was long believed that worry gave you ulcers.// ... pylori was a major risk factor, and the link with ... now report that people with generalized anxiety do seem to ...
... with animals say they have located the genes related ... they say it could one day lead to better ... research into this area was only able to locate ... of how the genes work together during memory formation. ...
... researchers observe that stress hormones may be disregulated in ... a hormonal system that helps the body deal with ... production of the stress hormone cortisol by the adrenal ... pains and overwhelming tiredness. It's cause is not well ...
Cached Medicine News:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate update and report second quarter 2014 financial ... Friday, August 1, 2014. That same day, Arena will ... Eastern Time (5:30 a.m. Pacific Time). ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... VIENNA, Va., Nov. 3 CEL-SCI Corporation,(NYSE: ... expanded its exclusive licensing,agreement for Multikine(R) with Orient ... from Taiwan. The new,agreement extends the Multikine collaboration ... New Zealand. The licensing agreement,initially focuses on the ...
... - Data presented at the 2008 iSBTc Annual Meeting ... at 11:00 a.m. ET to discuss,results -, BRANFORD, ... announced today preliminary data from an ongoing Phase II,trial ... treatment of patients with unresectable Stage III or Stage ...
Cached Medicine Technology:CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
... Portable - Battery Powered (6 size AA ... conversion (g, ct, oz, ozt, GN, dwt, ... Counting and Percent Measure functions, Auto Print. ... Optional AC adapter may be ordered for ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Medicine Products: